quarter of 2008, and the filing of a Phase I IND application
anticipated in late 2008.
CD59 Complement Inhibitor Program
- Selected to present a CD59-focused poster at AACR Annual Meeting.
- Generated a cell line producing humanized CD59 antibody that
successfully retained binding characteristics and potent in vivo
- Preparing to perform preclinical toxicology studies planned for
2008 in preparation for filing a Phase I IND application.
CD9 Cancer Stem Cell Program
- Selected to present a CD9-focused poster at AACR Annual Meeting.
- Presented positive findings demonstrating the ability of the lead
anti-CD9 antibody to kill cancer stem cells in an in vivo model
using cells from human leukemia patients at the American
Association of Cancer Research Special Conference on Cancer Stem
CD63 Antibody Program
- Licensed to Genentech, Inc. in March 2006, the CD63 program
continues to advance in preclinical studies in a variety of cancer
indications as part of a program to move the lead antibody towards
- Discovered and delivered novel antibodies to Takeda. Under the
terms of the research collaboration agreement, ARIUS has
successfully met its obligations to date and has received all
scheduled research payments from Takeda.
Additional Product Updates
- Currently, ARIUS has antibody programs targeting the MCSP antigen
and 37LRP, in addition to several other undisclosed programs.
- ARIUS currently has 23 issued or allowed patents covering its
antibody programs and discovery platform and over 228 patents
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved